Kindred Biosciences Inc (NASDAQ:KIN) Expected to Post Earnings of -$0.36 Per Share

Equities research analysts expect Kindred Biosciences Inc (NASDAQ:KIN) to post earnings of ($0.36) per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Kindred Biosciences’ earnings, with the highest EPS estimate coming in at ($0.32) and the lowest estimate coming in at ($0.38). Kindred Biosciences reported earnings of ($0.39) per share in the same quarter last year, which indicates a positive year over year growth rate of 7.7%. The firm is expected to announce its next earnings report on Wednesday, November 6th.

On average, analysts expect that Kindred Biosciences will report full-year earnings of ($1.52) per share for the current fiscal year, with EPS estimates ranging from ($1.62) to ($1.37). For the next year, analysts forecast that the business will post earnings of ($1.21) per share, with EPS estimates ranging from ($1.40) to ($0.88). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow Kindred Biosciences.

Kindred Biosciences (NASDAQ:KIN) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.01). Kindred Biosciences had a negative return on equity of 55.46% and a negative net margin of 1,583.00%. The company had revenue of $1.24 million during the quarter, compared to analysts’ expectations of $1.97 million.

KIN has been the topic of a number of recent research reports. BidaskClub raised Kindred Biosciences from a “sell” rating to a “hold” rating in a research note on Wednesday, August 7th. Cantor Fitzgerald set a $25.00 target price on Kindred Biosciences and gave the stock a “buy” rating in a research note on Friday, April 26th. Stifel Nicolaus initiated coverage on Kindred Biosciences in a research note on Wednesday, May 22nd. They issued a “buy” rating and a $14.00 target price on the stock. Barclays initiated coverage on Kindred Biosciences in a research note on Tuesday, June 11th. They issued an “overweight” rating and a $13.00 target price on the stock. Finally, ValuEngine raised Kindred Biosciences from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $14.28.

Several institutional investors have recently added to or reduced their stakes in KIN. PARK CIRCLE Co purchased a new stake in shares of Kindred Biosciences during the second quarter valued at $27,000. Bank of Montreal Can boosted its position in shares of Kindred Biosciences by 2,368.3% during the second quarter. Bank of Montreal Can now owns 3,505 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 3,363 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Kindred Biosciences during the first quarter valued at $53,000. BNP Paribas Arbitrage SA boosted its position in shares of Kindred Biosciences by 83,433.3% during the first quarter. BNP Paribas Arbitrage SA now owns 7,518 shares of the biopharmaceutical company’s stock valued at $69,000 after buying an additional 7,509 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY boosted its position in shares of Kindred Biosciences by 362.9% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 9,647 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 7,563 shares during the last quarter. 65.13% of the stock is currently owned by institutional investors.

Shares of NASDAQ KIN traded up $0.31 during trading on Friday, reaching $7.28. The company had a trading volume of 97,400 shares, compared to its average volume of 248,529. Kindred Biosciences has a 12-month low of $5.96 and a 12-month high of $15.20. The stock has a market cap of $272.26 million, a PE ratio of -4.55 and a beta of 0.38. The business’s 50-day moving average is $7.41 and its 200 day moving average is $8.70. The company has a quick ratio of 10.79, a current ratio of 11.36 and a debt-to-equity ratio of 0.01.

Kindred Biosciences Company Profile

Kindred Biosciences, Inc, a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

Featured Article: Catch-Up Contributions

Get a free copy of the Zacks research report on Kindred Biosciences (KIN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kindred Biosciences (NASDAQ:KIN)

Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.